Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds

Advertising today archive

3106 PWToday Stories

Cuts for NHS IT

08 Dec 09

Bidding hots up for Ratiopharm

13 Nov 09

Ratiopharm, the world’s fourth-largest generic drugs group are attracting major interest from seven trade buyers and private equity groups in a second round of bids.

In an interview in the FT earlier this year, Ratiopharm's CEO, Mr Windholz said he expected revenues to rise 8 per cent each year to €2.4bn in 2014 and profit on an earnings before interest, tax depreciation and amortisation basis to increase at an average annual rate of 20 per cent to €530m in the same period.

He said the group made a profit before interest, tax, depreciation and amortisation of almost €190m in the first nine months, unchanged year-on-year.

“Ratiopharm is in great health, we have a significantly positive cash flow, which pays for our investments,” he said in his first interview since he became head of the company in April 2008.

Ratiopharm is privately owned by the Merckle family in Germany, and sources previously put the company's value at EUR1.8 billion

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.